Accretion Nutraveda Reports FY26 Profit of ₹5.07 Crore Amid Board Changes

Accretion Nutraveda Ltd. has announced its audited financial results for the fiscal year ending March 31, 2026. The company reported a revenue from operations of ₹33.60 crore and a Profit After Tax (PAT) of ₹5.07 crore.

A significant development accompanying the financial results was a reshuffling of the company's board of directors. On May 8, 2026, two independent directors, Mr. Arun Dash and Mr. Mahipal Singh Chouhan, resigned from their positions. In their place, the board appointed two new Additional Non-Executive Independent Directors: Mr. Chand Rameshbhai Kanabar and Ms. Grishma A Shewale. These appointments are subject to shareholder approval.

The company also confirmed its audit partners for the upcoming fiscal year, FY2026-27. M/s. Sakhiya & Co. has been re-appointed as Secretarial Auditors, while M/s. UMT & Co. will serve as Internal Auditors.

Accretion Nutraveda recently completed an Initial Public Offering (IPO) that raised approximately ₹24.77 crore. As of March 31, 2026, the company held ₹655.48 lakh (₹6.55 crore) in unutilized IPO proceeds. Investors will likely focus on the strategy and timeline for deploying these funds.

The company operates within the nutraceutical and health products sector. Its peers in the broader health-related industry include pharmaceutical and biotechnology firms such as Panacea Biotec Ltd. and Ajanta Pharma Ltd.

Key areas for investor tracking will include the shareholder approval process for the new directors, management's plans for utilizing the remaining IPO funds, and future financial performance trends. The contributions of the new board members to corporate governance and strategic direction will also be closely watched.